- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.
Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.
Transcript (slightly modified)
Drug pricing is one area that Democrats and Republicans both agree on. Do you think they might be able to pass legislation addressing rising drug costs? What might it look like?
On drug costs, as with everything in healthcare, the best guess is always no change. I think both Democrats and Republicans are upset that there are people who can’t afford medications, but what they would do about it is very different, and therefore, the ability to compromise is going to be difficult here.
There are things they can do about the FDA, and they’re sort of doing a little bit of that, but the other major issues about things like prices of new medications, price increases, how much you can charge people who are uninsured, things like that, I don’t see a lot of agreement upon.
I think the wild card here is the President, whose sympathies on this seem to lie much more with the Democrats than with the Republicans. So if he decided he really wanted to do something there and he was going to work with the Democrats and bring things along, he really could force the issue more. I don’t know whether he will. So far, he’s governed as a very, very traditional right-wing Republican, and so if that’s the way he’s going to go, the odds that things happen will be very low.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
